Explore by health topic
View allGLP-1
Semaglutide, tirzepatide, retatrutide, side effects, dosing, and access.
Peptides
Recovery, metabolism, skin health, and evidence-based peptide guides.
Drug Guides
Plain-language coverage of major GLP-1 medications and comparisons.
Diet & Side Effects
Food, protein, fiber, nausea, fatigue, reflux, and long-term routines.
Latest
New guides from Middleway
GLP-1
Retatrutide and Cagrilintide Stack: Rationale, Risks, and Reality
People stack retatrutide (a triple agonist) with cagrilintide (an amylin analogue) hoping to hit appetite from two angles. The synergy is theoretical only. No human trial has tested this combination, and both drugs carry real safety questions.
Peptides
AOD-9604 vs Retatrutide: Two Very Different Fat-Loss Approaches
AOD-9604 is a growth-hormone fragment with weak human evidence, while retatrutide is a triple incretin agonist with strong phase 2 trial data. They are not in the same class, and the gap in proof is large.
GLP-1
Retatrutide and MOTS-c Stack: Metabolism, Energy, and Caveats
MOTS-c is a mitochondrial peptide that activates AMPK and is studied for metabolism and exercise. Some pair it with the triple agonist retatrutide, but no human stack data exists. Here is the rationale and the evidence gap.
GLP-1
Can You Combine Tesamorelin and Retatrutide?
Tesamorelin (a GHRH analogue for visceral fat) and retatrutide (an investigational triple agonist) target different pathways, so people ask about stacking them. No combined trial exists, and retatrutide is not FDA approved. Here is the rationale, the interactions, and the cautions.
Peptides
Best Growth Hormone Secretagogues in 2026: A Practical Guide
A clinical comparison of the main growth hormone secretagogues, including MK-677, ipamorelin, CJC-1295, sermorelin, GHRP-2/6, and tesamorelin. We cover how each works, what the evidence shows, side effects, and FDA status.
GLP-1
Retatrutide vs Zepbound: Weight Loss Comparison
Zepbound (tirzepatide) is an FDA-approved dual agonist that produced about 20.9% weight loss in SURMOUNT-1. Retatrutide is an investigational triple agonist that hit 24.2% in phase 2 and up to 28.3% in phase 3, but it is not yet approved.
GLP-1
How to Get Retatrutide in 2026: Every Legitimate Route
Retatrutide is an investigational Eli Lilly drug in Phase 3 trials, so there is no pharmacy or prescription route in 2026. This guide walks the only real path (clinical trial enrollment) plus the honest legal and safety reality of compounded and grey-market 'research' retatrutide.
GLP-1
Retatrutide For Sale: What to Check Before You Buy
Retatrutide is an investigational triple-agonist not approved by the FDA, so every vial sold online is research-use-only. This buyer-protection guide explains how to vet sellers, read a COA, spot scams, and sanity-check pricing before you part with money.
GLP-1
CagriSema vs Retatrutide: Which Wins on Weight Loss?
CagriSema (cagrilintide + semaglutide) delivered up to 22.7% weight loss in REDEFINE 1, while retatrutide reached 28.3% in its first pivotal phase 3 trial. Here is how the two next-generation obesity drugs compare on data, mechanism, dosing, and timeline.